Q32 Bio to Present at Oppenheimer Healthcare Conference Focusing on Immune Therapies

Q32 Bio Participates in Key Healthcare Conference

Q32 Bio Inc., listed under Nasdaq as QTTB, is poised to make an impactful presentation during the upcoming Oppenheimer 35th Annual Healthcare Life Sciences Conference scheduled for February 11, 2025. The clinical stage biotechnology company, recognized for its innovative biologic therapeutics aimed at revitalizing immune balance, will be delivering its insights through a virtual platform at 4 PM ET.

The company's participation underscores its commitment to the advancement of immune therapies specifically targeting autoimmune and inflammatory diseases. As a leader in this sector, Q32 Bio focuses on developing treatments that re-establish homeostasis within the immune system, addressing significant unmet needs in patient care. The event allows Q32 Bio's management to showcase their ongoing research and therapeutic programs, promising an exciting glimpse into the future of immunotherapy.

The presentation will also be accessible to the public via a webcast on the company's official website, www.q32bio.com. Those interested in the company's latest innovations will have the opportunity to view the archived replay, which will be available for a duration of 90 days after the event, ensuring wider access to their groundbreaking findings and discussions.

About Q32 Bio

Established as a pioneering clinical stage biotechnology entity, Q32 Bio is intensely focused on crafting biologic therapeutics that hone in on key regulators within both innate and adaptive immune systems. Their primary aim is to recalibrate immune responses in patients suffering from autoimmune conditions.

Among its leading initiatives, Q32 Bio is advancing bempikibart (ADX-914), which is a fully human anti-IL-7Rα antibody. This innovative therapy is currently undergoing Phase 2 trials and is designed to restore adaptive immune function, particularly beneficial for patients battling various autoimmune diseases. The IL-7 and TSLP pathways utilized in their approach have shown a significant genetic and biological role in driving harmful T cell-mediated responses affecting numerous conditions.

Additionally, Q32 Bio is progressing with its ADX-097 program, which also targets innate immunity pathways. This platform allows for the tissue-targeted regulation of the complement system, making it distinct from traditional systemic blockade methods prevalent in existing therapies. ADX-097 is in Phase 2 trials and is expected to bring forth new possibilities for complement therapy, emphasizing safety and precision.

Keeping the Public Informed

Q32 Bio is committed to transparent communication with its investors and the wider public, sharing updates via its website, social media platforms like X (formerly Twitter) and LinkedIn, as well as press releases. The company encourages stakeholders to keep abreast of their developments as they could significantly impact future therapeutic options for patients dealing with immune dysregulation.

As the healthcare landscape continues to evolve, Q32 Bio's participation in high-profile conferences like Oppenheimer reflects its strategic approach to innovation and patient-centered care, reinforcing its position as a key player in the biotechnology domain.

For continuous updates and detailed information about Q32 Bio's activities, advancements, and the progress of their clinical trials, visit www.Q32Bio.com.

In conclusion, the forthcoming presentation promises not only to highlight Q32 Bio's advancements but also to engage stakeholders in meaningful discussions about the future of immune therapeutics in the healthcare sector.